Inhibitors ANGPTL3 and their effects to hyperlipidemia and atherosclerosis

Angiopoietin-like protein 3 (ANGPTL3) has emerged as important regulators of lipid metabolism. Current innovative therapeutic options using monoclonal antibodies, antisense oligonucleotide (ASO) or vaccine approaches to block this protein may minimize the risk of atherosclerosis in dyslipidemic individuals. The purpose of this review is to discuss the effectiveness of these new ANGPTL3 inhibitors.